In Vitro Differentiation of T Cells from Murine Pluripotent Stem Cells

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2019 Aug 10

PMID 31396937

Authors

Xiaoniao Chen

Fengyang Lei

Liqiang Wang

Xiaofang Xiong

Jianxun Song

Affiliations

Soon will be listed here.

Abstract

In recent years cancer immunotherapy, especially the cell-based immunotherapy, has reached several milestones and achieved a lot of cancer remission in the clinics. Obtaining a more potent and effective cytotoxic T lymphocytes (CTLs) for cancer immunotherapy is always the ultimate goal for the researchers. However, the difficulty in harvesting a large number of tumor antigen-specific CTLs from the tumor patient is still a major obstacle we need to overcome. In our previous studies, it is shown that pluripotent stem cell-derived CTL-especially the genetically engineered antigen-specific CTLs-may serve as a good source of unlimited number of highly reactive and antigen-specific CTLs. Here we present a two-step method for the generation of antigen-specific T lymphocytes from iPS cells by in vitro priming and in vivo maturation.

References

Okita K, Ichisaka T, Yamanaka S . Generation of germline-competent induced pluripotent stem cells. Nature. 2007; 448(7151):313-7. DOI: 10.1038/nature05934. View

Lei F, Haque M, Sandhu P, Ravi S, Song J, Ni B . Development and characterization of naive single-type tumor antigen-specific CD8 T lymphocytes from murine pluripotent stem cells. Oncoimmunology. 2017; 6(7):e1334027. PMC: 5543906. DOI: 10.1080/2162402X.2017.1334027. View

Schmitt T, Zuniga-Pflucker J . Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity. 2002; 17(6):749-56. DOI: 10.1016/s1074-7613(02)00474-0. View

Hinrichs C, Borman Z, Gattinoni L, Yu Z, Burns W, Huang J . Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood. 2010; 117(3):808-14. PMC: 3035075. DOI: 10.1182/blood-2010-05-286286. View

Peerani R, Zandstra P . Enabling stem cell therapies through synthetic stem cell-niche engineering. J Clin Invest. 2010; 120(1):60-70. PMC: 2798701. DOI: 10.1172/JCI41158. View

Schuster S, Svoboda J, Chong E, Nasta S, Mato A, Anak O . Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017; 377(26):2545-2554. PMC: 5788566. DOI: 10.1056/NEJMoa1708566. View

Seki Y, Yang J, Okamoto M, Tanaka S, Goitsuka R, Farrar M . IL-7/STAT5 cytokine signaling pathway is essential but insufficient for maintenance of naive CD4 T cell survival in peripheral lymphoid organs. J Immunol. 2006; 178(1):262-70. DOI: 10.4049/jimmunol.178.1.262. View

Yang L, Baltimore D . Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci U S A. 2005; 102(12):4518-23. PMC: 553287. DOI: 10.1073/pnas.0500600102. View

Hataye J, Moon J, Khoruts A, Reilly C, Jenkins M . Naive and memory CD4+ T cell survival controlled by clonal abundance. Science. 2006; 312(5770):114-6. DOI: 10.1126/science.1124228. View

10.

Stemberger C, Huster K, Koffler M, Anderl F, Schiemann M, Wagner H . A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity. 2007; 27(6):985-97. DOI: 10.1016/j.immuni.2007.10.012. View

11.

Boztug K, Schmidt M, Schwarzer A, Banerjee P, Avedillo Diez I, Dewey R . Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med. 2010; 363(20):1918-27. PMC: 3064520. DOI: 10.1056/NEJMoa1003548. View

12.

Zhao Y, Parkhurst M, Zheng Z, Cohen C, Riley J, Gattinoni L . Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res. 2007; 67(6):2425-9. PMC: 2100408. DOI: 10.1158/0008-5472.CAN-06-3977. View

13.

Siewert C, Lauer U, Cording S, Bopp T, Schmitt E, Hamann A . Experience-driven development: effector/memory-like alphaE+Foxp3+ regulatory T cells originate from both naive T cells and naturally occurring naive-like regulatory T cells. J Immunol. 2007; 180(1):146-55. DOI: 10.4049/jimmunol.180.1.146. View

14.

Mendez-Ferrer S, Michurina T, Ferraro F, Mazloom A, MacArthur B, Lira S . Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010; 466(7308):829-34. PMC: 3146551. DOI: 10.1038/nature09262. View

15.

Lei F, Zhao B, Haque R, Xiong X, Budgeon L, Christensen N . In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance. Cancer Res. 2011; 71(14):4742-7. DOI: 10.1158/0008-5472.CAN-11-0359. View

16.

Himburg H, Muramoto G, Daher P, Meadows S, Russell J, Doan P . Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells. Nat Med. 2010; 16(4):475-82. PMC: 3689427. DOI: 10.1038/nm.2119. View

17.

Alajez N, Schmielau J, Alter M, Cascio M, Finn O . Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood. 2005; 105(12):4583-9. PMC: 1894994. DOI: 10.1182/blood-2004-10-3848. View

18.

Lei F, Haque R, Weiler L, Vrana K, Song J . T lineage differentiation from induced pluripotent stem cells. Cell Immunol. 2009; 260(1):1-5. DOI: 10.1016/j.cellimm.2009.09.005. View

19.

Boitano A, Wang J, Romeo R, Bouchez L, Parker A, Sutton S . Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010; 329(5997):1345-8. PMC: 3033342. DOI: 10.1126/science.1191536. View